Biogen is halting the development and commercialization of the Alzheimer’s drug Aduhelm, which drew intense scrutiny of its U.S. regulatory process due to concerns about whether its benefits outweighed its risks.
Top Capital is a comprehensive platform dedicated to providing the latest reviews, news, and insights on financial markets, investment opportunities, and top-ranked brokers. We aim to empower our users with expert analysis and recommendations to help them navigate the world of investing. Our site offers various subscription packages, giving users access to premium financial content tailored to their needs, including in-depth reviews and comparisons of leading financial service providers. While Top Capital does not directly provide trading or brokerage services, we deliver essential market data and analysis to help you make informed decisions. Advertisements featured on our website may generate compensation based on user interaction with the advertisers.
For more information about our platform, services, or to learn more about our subscription packages, please visit our About Us page or contact us.
Usage Restrictions: It is prohibited to use, store, reproduce, display, modify, transmit, or distribute the data from this website without prior written consent from Top Capital and/or the data provider. All intellectual property rights are reserved by Top Capital and/or the respective data providers.